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Histone acetylation, a type of chromatin modiﬁcation that allows increased gene transcription and can be
pharmacologically promoted by histone deacetylase (HDAC) inhibitors (HDACis), has been consistently
associated with promoting memory formation in the hippocampus. The basolateral nucleus of the amyg-
dala (BLA) is a brain area crucially involved in enabling hormones and drugs to inﬂuence memory forma-
tion. Here, we show that BLA activity is required for memory enhancement by intrahippocampal
administration of an HDACi. Two different HDACis, sodium butyrate (NaB) and trichostatin A (TSA), dif-
ferentially enhanced the retention of memory for inhibitory avoidance (IA) when administered to the
dorsal hippocampus after training. TSA showed a biphasic pattern of response during consolidation, in
which infusions given immediately or 3 h after training produced memory enhancement, whereas no
effect was observed when it was infused 1.5 or 6 h posttraining. Muscimol (MUS)-induced unilateral
functional inactivation of the BLA prevented the enhancement of memory retention produced by post-
training infusion of TSA into the ipsilateral hippocampus. TSA did not affect IA extinction or reconsolida-
tion. These results indicate that HDACis can increase IA memory retention when given into the
hippocampus, and, most importantly, BLA activity is necessary for enabling HDACi-induced inﬂuences
on memory formation.
 2014 Elsevier Inc. All rights reserved.1. Introduction
Gene expression associated with the formation of long-term
memories is regulated by epigenetic processes that alter the
chromatin state. Chromatin modiﬁcations allow for enduring alter-
ations in the patterns of cell function without the need for changes
in DNA sequence, thus constituting ideal candidate mechanisms
mediating long-term alterations induced by learning (Gräff & Tsai,
2013). Among the several types of epigenetic phenomena thatoccur in the brain and have been linked to memory formation, his-
tone acetylation is the best studied (Barrett & Wood, 2008; Bridi &
Abel, 2013; Gräff & Tsai, 2013; Levenson & Sweatt, 2005). Histones
constitute the major protein component of chromatin, and acetyla-
tion of their lysine residues by histone acetyltransferases (HATs)
disrupts the interaction between histone and DNA, resulting in a
‘‘relaxed’’ chromatin structure that allows increased gene readout.
An opposing role is played by histone deacetylases (HDACs), which,
by removing acetyl groups, promote chromatin condensation and
repress gene transcription (Haberland, Montgomery, & Olson,
2009; Kouzarides, 2007; Li, Carey, & Workman, 2007).
HDAC types are divided into four groups: class I (HDAC1 –
HDAC3 and HDAC8), class II (subdivided into class IIa, comprising
HDAC4, HDAC5, HDAC7 and HDAC9, and class IIb, consisting of
HDAC6 and HDAC10), class III (sirtuins), and class IV (HDAC11).
All class I, II, and IV HDACs are expressed in neurons (Broide
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of memory for contextual fear conditioning is accompanied by an
increase in histone H3 acetylation in the CA1 area of the dorsal hip-
pocampus (Levenson et al., 2004). Overexpression of HDAC2 in
mice impairs memory and long-term potentiation (LTP) in the hip-
pocampus, whereas knocking it out enhances memory (Guan et al.,
2009), and HDAC3 deletion in the dorsal hippocampus enhances
contextual fear (McQuown et al., 2011). HDAC2 content is in-
creased in the CA1 hippocampal area in mouse models of neurode-
generation as well as in the brains from patients with Alzheimer’s
disease, and an epigenetic blockade of gene transcription mediated
by HDAC2 was associated with memory dysfunction in experimen-
tal neurodegeneration models (Gräff et al., 2012).
The use of HDAC inhibitors (HDACis) is the most widely inves-
tigated pharmacological approach to produce memory enhance-
ment through manipulating the epigenome. The HDACis most
frequently used in memory experiments include sodium butyrate
(NaB), trichostatin A (TSA), suberoylanilide hydroxamic acid
(SAHA), and valproic acid (VPA). All these drugs inhibit preferen-
tially class I HDACs, which are localized predominantly to the cell
nucleus, and also act with lower activity on HDAC8. TSA and SAHA
also inhibit HDAC6, the main cellular cytoplasmic deacetylase
(Bhalla, 2005; Bolden, Peart, & Johnstone, 2006; Nott, Fass, Hag-
garty, & Tsai, 2013). TSA facilitates LTP in the CA1 hippocampal
area (Vecsey et al., 2007) as well as in amygdala slices (Monsey,
Ota, Akingbade, Hong, & Schafe, 2011). Systemic administration
of NaB or VPA enhances fear memory formation and extinction
(Bredy & Barad, 2008; Lattal, Barrett, & Wood, 2007; Levenson
et al., 2004; Stafford, Raybuck, Ryabinin, & Lattal, 2012). Intrahip-
pocampal administration of TSA immediately after training en-
hances long-term contextual fear memory (Vecsey et al., 2007),
whereas NaB enhances fear extinction (Stafford et al., 2012) in
mice. In addition to fear-motivated memory, studies using either
systemic injections of NaB or posttraining intrahippocampal infu-
sions of NaB, TSA, or the class I HDAC-selective inhibitor MS275
have found enhancement of long-term memory for speciﬁc types
of object location or object recognition tasks in rats or mice (Haet-
tig et al., 2011; Hawk, Florian, & Abel, 2011; Reolon et al., 2011;
Roozendaal et al., 2010; Silva et al., 2012; Stefanko, Barrett, Ly,
Reolon, & Wood, 2009).
Extensive evidence indicates that normal activity of the basolat-
eral nucleus of the amygdala (BLA) is required to mediate drug
inﬂuences on memory consolidation for emotionally-arousing
tasks (McGaugh, 2002; McGaugh, Cahill, & Roozendaal, 1996;
McIntyre, McGaugh, & Williams, 2012; Roesler & McGaugh,
2010). Selective lesions, functional inactivation, or pharmacologi-
cal inhibition of the BLA block the effects of systemically adminis-
tered drugs and hormones on memory (Quirarte, Roozendaal, &
McGaugh, 1997; Roesler et al., 2004; Roozendaal & McGaugh,
1996). The BLA is also required for enabling the memory-enhanc-
ing effects of drugs infused directly into the hippocampus or re-
lated brain areas. Experiments using inhibitory avoidance (IA)
showed that BLA lesions or intra-BLA administration of a noradren-
ergic antagonist can prevent the enhancement produced by post-
training intrahippocampal infusion of glucocorticoid receptor
agonists on memory consolidation (Roozendaal & McGaugh,
1997; Roozendaal, Nguyen, Power, & McGaugh, 1999), and excito-
toxic lesions of the BLA block the memory-enhancing effect of
administration of the cAMP analog 8-Br-cAMP into the entorhinal
cortex (Roesler, Roozendaal, & McGaugh, 2002). The functional
interaction between the BLA and the hippocampus is restricted
to the ipsilateral hemisphere. Thus, induction of hippocampal LTP
is impaired by lesions of the ipsilateral BLA (Ikegaya, Saito, &
Abe, 1994), and inhibition of the noradrenergic system in the ipsi-
lateral, but not the contralateral, BLA blocks the memory-enhanc-
ing effects of a glucocorticoid receptor agonist infused into thedorsal hippocampus (Roozendaal et al., 1999). In addition, expres-
sion of the immediate-early gene Arc in the dorsal hippocampus is
increased by administration of the b-adrenoreceptor agonist clen-
buterol into the ipsilateral BLA.
Also, the BLA–hippocampal interaction seems to be speciﬁc to
the dorsal part of the hippocampus, since intra-BLA clenbuterol
does not affect Arc expression in the ventral hippocampus
(McIntyre et al., 2005). It is possible that the nucleus accumbens
(NAc) is a critical site of convergence between the BLA and the dor-
sal hippocampus. The BLA projects directly to the NAc via the stria
terminalis (ST), and the NAc in turn also receives direct projections
from the hippocampus. Lesioning either the ST or the NAc blocks
the memory enhancement induced by administration of a gluco-
corticoid receptor agonist into the BLA or the dorsal hippocampus
(Roozendaal, de Quervain, Ferry, Setlow, & McGaugh, 2001).
Although the effects of HDACis on memory have been increas-
ingly investigated, little is known about the time course of HDACi
enhancement of consolidation. In addition, previous studies have
not veriﬁed whether the BLA inﬂuences the actions of HDACis gi-
ven into other brain areas. In the present study, we describe the ef-
fects of administering NaB and TSA to the dorsal hippocampus on
the consolidation of memory for IA, and examine the requirement
of intact BLA activity in mediating the memory-enhancing effect of
TSA.2. Methods
2.1. Animals
Adult male Wistar rats (280–320 g at time of surgery) were ob-
tained from the institutional breeding facility (CREAL, ICBS, UFRGS)
and maintained at the university hospital experimental animal
facility (UEA, CPE-HCPA). Animals were housed ﬁve per cage in
plastic cages with sawdust bedding, and maintained on a 12 h
light/dark cycle at a room temperature of 22 ± 1 C. The rats were
allowed ad libitum access to standardized pellet food and water.
All experiments took place during the light phase of the cycle,
between 8 AM and 4 PM. All experimental procedures were
performed in accordance with the Brazilian Guideline for the Care
and Use of Animals in Research and Teaching (DBCA, published by
CONCEA, MCTI; http://www.mct.gov.br/upd_blob/0226/226494.
pdf) and were approved by the institutional animal care committee
under protocol number 120068.
2.2. Surgery
Animals were implanted under anesthesia with ketamine
(75 mg/kg) and xylasine (25 mg/kg) with either unilateral (left
hemisphere) or bilateral 8.0-mm, 23-gauge guide cannulae aimed
1.0 mm above the CA1 area of the dorsal hippocampus, or unilate-
ral (left hemisphere) 14-mm 23-gauge guide cannulae aimed
1.0 mm above the BLA, as described in previous reports (Jobim
et al., 2012; Roesler et al., 2004; Roesler et al., 2006). Coordinates
(BLA, anteroposterior, 2.8 mm from bregma, mediolateral,
±4.8 mm from bregma, ventral, 7.5 mm from skull surface; DH
anteroposterior, 4.3 mm from bregma; mediolateral, ±3.0 mm
from bregma; ventral, 2.0 mm from skull surface) were obtained
from the atlas of Paxinos and Watson (2007). Animals were al-
lowed to recover at least 7 days after surgery.
2.3. Intrahippocampal infusions and BLA inactivation
The general procedures for intrahippocampal infusions were as
described in previous reports (Jobim et al., 2012; Roesler et al.,
2006). At the time of infusion, a 30-gauge infusion needle was
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truded 1.0 mm beyond the guide cannula and was aimed at either
the BLA or the dorsal hippocampus. Drug or its respective control
solution (saline or vehicle) was infused during a 30-s period. The
infusion needle was left in place for an additional minute to allow
diffusion of the drug away from the needle tip.
In experiments examining the effect of intrahippocampal
administration of HDACis on memory consolidation, rats received
a bilateral 1.0-ll infusion of NaB (Sigma–Aldrich, St. Louis, USA;
55, 100, or 250 mM) dissolved in saline (SAL, 0.9% NaCl), or TSA (Sig-
ma–Aldrich; 22 mM) dissolved in 50% ethanol in saline (vehicle,
VEH; Vecsey et al., 2007), into the hippocampus immediately after
training. Control animals received SAL in experiments using NaB
and VEH in experiments using TSA. In the experiment examining
the possible effects of TSA on reconsolidation or extinction, animals
were given a bilateral 1.0-ll infusion of TSA (22 mM) or VEH imme-
diately after the ﬁrst test trial. In the experiment focusing on the
possible BLA requirement for TSA-induced memory enhancement,
unilateral functional inactivation of the left BLA was carried out
as previously described (Roesler et al., 2004) by giving rats a unilat-
eral 0.5-ll infusion of the c-aminobutyric acid type A (GABAA)
receptor agonist muscimol (MUS) (0.5 lg) (Sigma–Aldrich)
dissolved in SAL into the left BLA 5 min before training. Control ani-
mals received an infusion of SAL. Immediately after training, the
same animals were given a unilateral 1.0-ll infusion of VEH or
TSA (22 mM) into the left dorsal hippocampus. In all experiments,
drug dose ranges and appropriate vehicles were chosen on the basis
of previous studies (Hawk et al., 2011; Lattal et al., 2007; Roo-
zendaal et al., 2010; Stafford et al., 2012; Vecsey et al., 2007). Drug
solutions were freshly prepared before each experiment.
2.4. Inhibitory avoidance (IA)
Single-trial step-down IA is an established model of fear-moti-
vated conditioning. In this task, animals learn to associate a location
in the training apparatus (a grid ﬂoor) with an aversive stimulus
(footshock). The general procedures for IA behavioral training and
retention test were described in previous reports (Jobim et al.,
2012; Roesler et al., 2004; Roesler et al., 2006). The IA training appa-
ratus was a 50  25  25-cm acrylic box (Albarsch, Porto Alegre,
Brazil) whose ﬂoor consisted of parallel caliber stainless steel bars
(1 mmdiameter) spaced 1 cm apart. A 7-cmwide, 2.5-cm high plat-
form was placed on the ﬂoor of the box against the left wall.
On training trials, rats were placed on the platform and their la-
tency to step down on the grid with all four paws was measured
with a digital chronometer. Immediately after stepping down on
the grid, rats received a 0.4-mA, 3.0-s footshock and were removed
from the apparatus immediately afterwards. Retention test trials
took place at different intervals after training by placing the rats
on the platform and recording their latencies to step down (see
Section 3 for detailed procedures for each experiment). Depending
on the experiment, rats were given up to six test trials. No foot-
shock was presented during retention test trials. In the experiment
examining possible drug effects on reconsolidation, rats that did
not step down to the grid ﬂoor within 300 s during the 24-h test
trial (‘‘reactivation session’’) were gently led by experimenter to
the grid ﬂoor. Step-down latencies on the retention test trial (max-
imum 300 s) were used as a measure of IA memory retention. In
some of the experiments, at the end of series of test trials, rats were
given a 0.3-mA reminder footshock (Tronel & Alberini, 2007),
followed by a retention test 24 h later.
2.5. Histology
Twenty-four to 72 h after behavioral testing, a 1.0- or 0.5-ll
infusion of a 4% methylene blue solution was given into the dorsalhippocampus or BLA respectively. Rats were killed by decapitation
15 min later, and their brains were removed and stored in 10% for-
malin for at least 72 h. The brains were sectioned and examined for
cannulae placements. The extension of the methylene blue dye was
taken as indicative of diffusion of the drugs previously given to
each rat, as previously described (Jobim et al., 2012; Roesler
et al., 2004; Roesler et al., 2006). Rats with incorrect cannula place-
ments were excluded from the analysis.2.6. Statistics
Data are shown as mean + S.E.M. retention test latencies to
step-down (s). Comparisons of training and retention test step-
down latencies between control and drug-treated groups were
performed using Kruskal–Wallis analysis of variance and Mann–
Whitney U tests, two-tailed (Jobim et al., 2012; Roesler et al.,
2004; Roesler et al., 2006). In all comparisons, p < 0.05 was consid-
ered to indicate statistical signiﬁcance.3. Results
3.1. Enhancement of IA memory consolidation by posttraining
administration of NaB into the dorsal hippocampus
The ﬁrst experiment examined the effect of posttraining intra-
hippocampal administration of NaB on the retention of IA memory.
Rats were given IA training followed by an infusion of SAL (N = 10)
or NaB (55 mM, N = 10; 100 mM, N = 10; or 250 mM, N = 8) into the
CA1 hippocampal area immediately after training. All rats were
tested for retention 1 (Test 1), 2 (Test 2), 3 (Test 3), and 4 (Test
4) days after training. Based on the results showing that only the
highest dose (250 mM) of NaB produced a signiﬁcant effect, rats
treated with this dose were given additional test trials at 11 (Test
5), and 21 (Test 6) days after training. Immediately after Test 6, rats
were given a reminder footshock and tested again 1 day later.
Results are shown in Fig. 1. There were signiﬁcant differences
between SAL-treated rats and rats given NaB at 250 mM in Test 1
(p < 0.01), Test 2 (p < 0.05), and Test 3 (p < 0.01), but not in the
other behavioral trials. There were no signiﬁcant differences be-
tween the SAL group and groups given NaB at 55 or 100 mM. There
was a decline in retention levels across test trials, and both groups
displayed similarly high latencies when tested after a reminder
shock. The results indicate that NaB at the highest dose used pro-
duced an enhancement of IA memory retention that persisted for
3 days.3.2. Time course of consolidation enhancement by intrahippocampal
administration of TSA
Next, we aimed to compare the effects of posttraining NaB with
those of TSA. Rats were trained as described above and given an
infusion of VEH (N = 11) or TSA (22 mM, N = 13) into the hippo-
campus immediately after training. Retention tests were carried
out 1 (Test 1), 2 (Test 2), 3 (Test 3), 4 (Test 4), 11 (Test 5), and
21 (Test 6) days after training. Immediately after Test 6, animals
received a reminder footshock and were tested again 1 day later.
There were signiﬁcant differences between rats given VEH and
TSA in Test 1 (p < 0.05), Test 2 (p < 0.01), Test 3 (p < 0.01), Test 4
(p < 0.05), and Test 5 (p < 0.05), but not in other behavioral trials.
As in the previous experiment, one can observe a reduction in
retention levels across test trials, and both groups displayed high
latencies when tested after a reminder shock (Fig. 2A). The results
indicate that TSA administration resulted in signiﬁcant enhance-
ment of IA memory retention that lasted for 11 days.
Fig. 1. Administration of NaB into the hippocampus enhances long-term retention of IA memory. Rats were trained and given an infusion of SAL (N = 10) or NaB (55 mM,
N = 10; 100 mM, N = 10; or 250 mM, N = 8) into the CA1 hippocampal area immediately after training. All rats were tested for retention 1 (Test 1), 2 (Test 2), 3 (Test 3), and 4
(Test 4) days after training. Animals treated with 250 mM NaB were given additional test trials at 11 (Test 5), and 21 (Test 6) days after training. Immediately after Test 6, rats
were given a reminder footshock and tested again 1 day later. Data are mean + S.E.M. retention test latencies to step-down (s); p < 0.05 and p < 0.01 compared to SAL-
treated rats.
Fig. 2. Biphasic enhancement of long-term memory for IA by intrahipocampal administration of TSA. (A) Rats were given IA training followed by an infusion of VEH (N = 11)
or TSA (22 mM, N = 13) into the hippocampus. Retention was tested 1 (Test 1), 2 (Test 2), 3 (Test 3), 4 (Test 4), 11 (Test 5), and 21 (Test 6) days after training. Immediately after
Test 6, animals received a reminder footshock and were tested again 1 day later. (B) Rats were trained and tested as described above, but infusion of VEH or TSA (22 mM, N = 7
rats per group) was given 1.5 h after training. (C) Rats were trained and tested as above, but infusion of VEH or TSA (22 mM, N = 9 rats per group) was given 3 h after training;
(D) VEH or TSA (N = 11 rats per group) was infused 6 h after training, and retention was tested 1 (Test 1), 2 (Test 2), 3 (Test 3), and 4 (Test 4) days later. Data are mean + S.E.M.
retention test latencies to step-down (s); p < 0.05 and p < 0.01 compared to VEH-treated rats.
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of use. When rats were trained and tested as above, but TSA was
infused 1.5 h after training, no signiﬁcant effect of TSA was ob-
served (Fig. 2B; N = 7 rats per group). In contrast, an infusion given
3 h after training produced signiﬁcantly enhanced retention in
Tests 1, 2, and 3 (N = 9 rats per group; all ps < 0.05) (Fig. 2C). Final-
ly, TSA infusions given 6 h posttraining had no signiﬁcant effect on
memory tested up to 4 days after training (Fig. 2D; N = 11 rats per
group). Due to the clear lack of drug effect, rats in this experiment
were no further tested (see Figs. 3 and 4)
3.3. Functional inactivation of the BLA prevents memory enhancement
by intrahippocampal TSA administration
We then examined whether a functionally active BLA was re-
quired for intrahippocampal TSA to enhance memory. Rats were
given a unilateral infusion of SAL or MUS into the left BLA before
IA training, and a unilateral infusion of VEH or TSA into the hippo-
campus immediately after training as described in Section 2. Theresulting experimental groups were SAL/VEH (N = 11); SAL/TSA
(N = 15); MUS/VEH (N = 11); and MUS/TSA (N = 11). A retention
test trial was carried out 24 h later. TSA administration induced a
signiﬁcant enhancement of retention (p < 0.001) in rats given in-
tra-BLA SAL, whereas animals infused with MUS showed retention
levels that did not differ from those in the control group, regardless
of whether they received intrahippocampal VEH or TSA after train-
ing (Fig. 3). These results indicate that MUS-induced BLA inhibition
prevented the TSA enhancement of IA retention.3.4. Post-retrieval administration of TSA into the hippocampus does
not affect IA memory
In order to verify whether TSA would affect processes related to
extinction or reconsolidation, rats were trained and tested for
retention 1 day later (Test 1). Immediately after Test 1, an infusion
of VEH (N = 14) or TSA (N = 11) was given into the hippocampus.
Retention was tested again 1 day after the infusion (Test 2). There
Fig. 3. Memory enhancement induced by TSA administration into the hippocampus
requires the BLA. Rats were given a unilateral infusion of SAL or MUS (0.5 lg) into
the left BLA before IA training, and a unilateral infusion of VEH or TSA (22 mM) into
the hippocampus immediately after training (SAL/VEH, N = 11; SAL/TSA, N = 15;
MUS/VEH, N = 11; MUS/TSA, N = 11). Retention was tested 24 h later. Data are
mean + S.E.M. retention test latencies to step-down (s); p < 0.001 compared to
SAL/VEH controls.
Fig. 4. Administration of TSA into the hippocampus does not affect IA memory
when given after retrieval. Rats were trained and given a retention test trial 1 day
later (Test 1). Immediately after Test 1, VEH (N = 14) or TSA (22 mM; N = 11) was
infused into the hippocampus. Retention was tested again 1 day after the infusion
(Test 2). Data are mean + S.E.M. retention test latencies to step-down (s). There
were no signiﬁcant differences between groups.
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TSA given after retrieval did not affect IA memory Fig. 4.
3.5. Histology
All animals included in the ﬁnal analysis (189 rats) had cannula
placed in the intended sites. Fig. 5 shows schematic drawings of
the diffusion of methylene blue, which indicates infusion place-
ments and spread of drug infusions, within the dorsal hippocam-
pus and BLA.
4. Discussion
The novel ﬁndings reported here can be summarized as follows:
(1) administration of the HDACis, NaB or TSA, into the dorsal hip-
pocampus immediately after training enhanced retention of mem-
ory for IA; (2) The enhancement induced by TSA showed a biphasic
temporal pattern during consolidation, in which memory retentionwas signiﬁcantly enhanced by infusions given immediately after or
3 h training, but not when the drug was administered 1.5 or 6 h
after training; (3) The enhancing effect of TSA infused unilaterally
into the dorsal hippocampus was completely prevented by MUS-
induced functional inactivation of the ipsilateral BLA; and (4) TSA
given immediately after retrieval did not affect retention of IA
memory.
Perhaps the most important ﬁnding of the present study was
that functional inactivation of the BLA blocked the memory-
enhancing effect of intrahippocampal TSA (Fig. 6). As previously
shown (Roesler et al., 2004), unilateral inhibition of the left BLA in-
duced by a high dose of MUS before training did not signiﬁcantly
affect IA memory retention per se, but could prevent the effect of
another pharmacological intervention on memory consolidation.
This is strongly consistent with the view that the BLA has a general
and critical role as a brain area required to enable the inﬂuence of
endogenous hormones, as well as of systemic or localized adminis-
tration of drugs, on memory consolidation (McGaugh, 2002;
McGaugh et al., 1996; McIntyre et al., 2012). The present ﬁndings
provide the ﬁrst evidence indicating that this view should be ex-
tended to encompass epigenetic modulators, such as HDACIs, as
agents that require BLA activity in order to be able to inﬂuence
memory in other brain areas.
Previous studies have indicated that HDACis can enhance mem-
ory formation or extinction by increasing the acetylation of speciﬁc
histone residues, such as histone 3 lysine residues 9 and 14 (H3K9/
14), resulting in enhanced expression of genes related to synaptic
plasticity and memory (Gräff & Tsai, 2013). Facilitation of
hippocampal memory and LTP by HDACis was shown to involve
transcriptional activation mediated by cAMP-response element-
binding protein (CREB)-binding protein (CBP). Probably through
this mechanism, TSA administration into the mouse hippocampus
results in a selective and transient increase in the expression of
genes related to synaptic plasticity and contextual fear, including
Nr4a1, Nr4a2, and NGFI-B (nerve growth factor inducible-B) (Vec-
sey et al., 2007). A recent seminal study showed that, in hippocam-
pal extracts from mice given extinction training, systemic
administration of the selective inhibitor of class I HDACs, CI-994,
was associated with the differential expression of 475 genes be-
tween controls and CI-994-treated animals. Genes involved in hip-
pocampal memory shown to be upregulated in response to CI-994
paired with extinction training included Arc, cFos, Npas4, and Igf2.
These changes were accompanied by increased glucose utilization,
facilitated LTP, enhanced dendritic branching, and an increase in
the number of dendritic spines, in the hippocampi of mice given
CI-994 (Gräff et al., 2014).
The discussion on candidate mechanisms mediating the mem-
ory-enhancing effects of HDACis is further complicated because
histones are not the only molecular targets of HDACis, which can
also display activities independent of histone regulation of gene
expression. For instance, transcription factors including E2F1,
STAT1, STAT3, and NF-jB might be directly hyperacetylated by
HDACis (Bolden et al., 2006; Glozak, Sengupta, Zhang, & Seto,
2005; Johnstone & Licht, 2003), and in vitro experiments using
brain tumor cells have indicated that TSA may inﬂuence protein ki-
nase signaling through an acetylation-independent mechanism
involving a disruption of HDAC-protein phosphatase 1 (PP1) com-
plexes (Chen, Weng, Tseng, Lin, & Chen, 2005). The possibility that
HDACi induce effects directly on signaling pathways in the cyto-
plasm is particularly relevant for studies using TSA, which inhibits
HDAC6, a predominatly cytoplasmic histone deacetylase, which
likely has several mechanisms of action independent of alterations
in gene expression mediated by increased histone acetylation
(Chen et al., 2005; Glozak et al., 2005; Johnstone & Licht, 2003).
In this regard, it is interesting to speculate on the mechanisms
underlying our somewhat surprising ﬁnding that the time course
Fig. 5. Infusion placements into the hippocampus and BLA. Schematic diagrams of coronal sections of the rat brain, adapted from the atlas of Paxinos and Watson (2007),
depicting the diffusion of methylene blue in the (A) dorsal hippocampus and (B) left BLA for rats included in the statistical analysis.
Fig. 6. A model of BLA requirement for HDACi-induced memory enhancement in
the hippocampus. Normal BLA activity may be necessary to enable the inﬂuence of
drugs acting on HDACs on memory consolidation. Muscimol-induced functional
inactivation of the BLA prevents the memory-enhancing effect of intrahippocampal
administration of TSA after training.
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showed a biphasic pattern, in which the effect was observed with
infusions given shortly after training or 3 h later, but not at an
intermediate time point. These ﬁndings support evidence from a
previous study, which used the context-signal memory task in
the Chasmagnathus granulatus crab to examine the time course of
histone acetylation and HDACi effects during memory consolida-
tion. The authors found that NaB injections resulted in memory
enhancement when given immediately or 6 h posttraining, but
not at 3 or 12 h after training, which is consistent with the two
phases of PKA activity involved in consolidation in crabs (Feder-
man, Fustiñana, & Romano, 2009). In rats, similar patterns of two
waves of drug effects in the hippocampus during consolidation of
IA memory have previously been observed in experiments using
a protein synthesis inhibitor (Quevedo et al., 1999) or drugs acting
on the cAMP/protein kinase A (PKA)/CREB signaling pathway
(Bevilaqua et al., 1997). These effects are consistent with the
well-established requirement of two waves of protein synthesisand PKA activity in the hippocampus for memory formation (Abel
et al., 1997; Alberini, 2009; Kandel, 2012). However, the mecha-
nisms and time course of action of HDACis do not necessarily pre-
dict that their effects should display a similar two-phase pattern.
Histone H3 acetylation in the mouse hippocampus was found to
be signiﬁcantly increased 4 h after intrahippocampal TSA adminis-
tration (Vecsey et al., 2007), making it unexpected that TSA infu-
sions separated by short time intervals could produce markedly
different effects, as was the case in our experiment. On the other
hand, some effects of TSA seem to be more transient. Thus, the
expression of Nr4a1 was signiﬁcantly increased 2 h after TSA infu-
sion and fear conditioning, but returned to normal levels by 4 h
after conditioning (Vecsey et al., 2007). It is possible that extra-epi-
genetic effects of TSA, such as interactions with proteins involved
in cell signaling in the cytoplasm (Chen et al., 2005; Glozak et al.,
2005), rather than long-lasting alterations in gene expression, are
predominantly involved in the TSA inﬂuences on consolidation.
In addition, TSA might be more effective in modulating consolida-
tion when its administration coincides with the waves of activation
of protein synthesis and PKA activity in the hippocampus.
Although detailing the mechanisms underlying the effects of TSA
infusion given at different time points after learning falls out of
the scope of the present study, future experiments should conﬁrm
and further explore the observed biphasic pattern for the effects of
TSA infusions given during consolidation.
Another aspect of our ﬁndings was related to the persistence of
memory enhancement by HDACis, which is consistent with previ-
ous evidence indicating that increased acetylation induced by
HDACis is a molecular feature of stronger and more persistent
memories (Federman et al., 2009). Compared to controls, rats given
NaB shortly after training, or TSA 3 h postraining, showed signiﬁ-
cantly enhanced retention for 3 days, whereas in rats given TSA
immediately after training the effect persisted for 11 days. How-
ever, for both drugs, memory retention eventually returned back
to basal levels in a relatively short period of time. It should be
pointed out, however, that a proper evaluation of the effects of
HDACis on memory persistence would require experiments using
different animals tested at different time points, as well as dose–
response curves for all the drugs used. In step-down IA, repeated
exposure to test trials in the absence of footshock exposure usually
results in memory extinction, which can be inﬂuenced by drugs
given upon retrieval (Vianna, Szapiro, McGaugh, Medina, &
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fect when given after training and not after retrieval, it cannot be
ruled out that the decline in memory retention across multiple
retention test trials was inﬂuenced by a differential processing of
extinction in rats given posttraining HDACis compared to controls.
When TSA was infused after retrieval (i.e., post-ﬁrst retention
test) no signiﬁcant alteration in IA memory retention tested
1 day later was observed. This is in contrast with previous reports
showing that systemic or intrahippocampal administration of
HDACis after retrieval can accelerate extinction of different types
of conditioning (Bredy & Barad, 2008; Fujita et al., 2012; Gräff
et al., 2014; Itzhak, Anderson, Kelley, & Petkov, 2012; Lattal &
Wood, 2013; Lattal et al., 2007; Malvaez, Sanchis-Segura, Vo, Lat-
tal, & Wood, 2010; Malvaez et al., 2013; Raybuck, McCleery, Cunn-
ingham, Wood, & Lattal, 2013; Stafford et al., 2012; Wang, Zhang,
Qing, Liu, & Yang, 2010). Moreover, overexpression of HDAC1 in
the mouse hippocampus (Bahari-Javan et al., 2012) or knockout
of the HDAC2 gene in postmitotic forebrain neurons (Morris, Mah-
goub, Na, Pranav, & Monteggia, 2013) predominantly affects
extinction. Other studies have shown that HDACis administered
systemically or into the amygdala around retrieval can lead to
memory enhancement, an effect that has been interpreted as a
facilitation of reconsolidation-like processes (Bredy & Barad,
2008; Maddox & Schafe, 2011). Although pharmacological manip-
ulation of the dorsal hippocampus after retrieval, using protocols
similar to the one used in the present study, is capable of affecting
both extinction and reconsolidation of IA memory (Jobim et al.,
2012; Luft et al., 2006; Vianna et al., 2001), it remains unclear
which speciﬁc experimental parameters and boundaries determine
the outcome of post-retrieval interventions in IA. Further experi-
ments exploring different training, testing, and drug administra-
tion conditions are required to establish whether HDACis can
inﬂuence retrieval-dependent memory modiﬁcations in this task.
In summary, here we show that the enhancement of IA memory
consolidation produced by administration of an HDACi into the
dorsal hippocampus depends on a functionally intact BLA. This is
the ﬁrst evidence indicating a critical role of the BLA in enabling
memory enhancement by manipulation of epigenetic mechanisms
in another brain area.
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